About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Endocrinology
General Surgery
Hematology
Nephrology
Neurosurgery
Oncology
Oral Maxillofacial
Orthopaedics
Pediatrics
Plastic Surgery
Podiatry
Primary Care
Pulmonology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
Chemotherapy vs. Chemo Free in Indolent Non-Hodgkin Lymphoma - Can We Improve Outcomes With Emerging Agents?
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Nathan H. Fowler
October 2019
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
Moffitt Cancer Center
16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Sat, Jan 18, 2020
8th ESO-SIOP Europe Masterclass in Paediatric Oncology
8th ESO-SIOP Europe Masterclass in Paediatric Oncology
Sat, Jun 6, 2020
Indy Hematology Review
17th Indy Hematology Review
Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Fri, Feb 7, 2020
19:49
2018 Pan Pacific Lymphoma Conference
Cutaneous T-cell Lymphoma: Management of Transformed Mycosis Fungoides a...
Feat.
Y. Kim
12:53
KU Hematology & Medical Oncology Review 2019
ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R/R DLBC...
Feat.
M. Hoffmann
24:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIET an...
Feat.
F. Locke
06:12
Indy Hematology Review
New Approaches in DLBCL
Feat.
J. Leonard
30:08
City of Hope
Advances in Therapy in Cutaneous T Cell Lymphoma
Feat.
C. Querfeld
15:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
PI3Ki's in Indolent Lymphoma: Overview of Approved Drugs, Trial Based Da...
Feat.
A. Zelenetz
10:24
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Double-Hit Lymphoma Diagnosis, Initial and Relapsed/Refractory Treatment...
Feat.
K. Dunleavy
08:39
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Next Questions in Hodgkin Lymphoma: Brentuximab Vedotin/PD-1+AVD as Fron...
Feat.
S. Ansell
07:27
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Plasmablastic Lymphoma: Survival Analysis of a SEER Database (2010-2016)...
Feat.
J. Florindez
12:54
Craig Portell
Untreated Follicular Lymphoma - Treatment Options for Patients with Earl...
13:27
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
Treatment of Primary CNS Lymphoma: Upfront Regimen, Surgery, Treatment o...
Feat.
C. Grommes
14:46
Indy Hematology Review
Treatment of Follicular Lymphoma and Other Indolent Lymphomas: Is Target...
Feat.
B. Cheson
15:50
Indy Hematology Review
Treatment Algorithm for DLBCL
Feat.
J. Leonard
21:11
2018 Pan Pacific Lymphoma Conference
Use of Total Metabolic Tumor Volume in PET Scans
Feat.
N. Hansen
20:51
Carla Casulo
Prognostic Markers in Follicular Lymphoma, FLIPI Score and Results of PR...
16:50
Moffitt Cancer Center
Management and Prevention of CAR-T Toxicities
Feat.
B. Shah
17:49
Jonathan Friedberg
How to Improve on RCHOP for DLBCL: Role of Novel Agents
07:40
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Oral Abstract NHL 088: Angiogenesis’ Related Polymorphism Emerges as Pro...
Feat.
A. Brito
12:35
Jonathon Cohen
Current Approaches to Evaluation and Management of Mantle Cell Lymphoma
10:46
2018 Pan Pacific Lymphoma Conference
New Approaches to Initial treatment of DLBCL: R-CHOP +
Feat.
N. Bartlett